Cytospire Secures £61M Series A to Advance Cancer Drugs
Cytospire Therapeutics has secured £61 million in Series A funding to advance its cancer treatment technology into clinical trials. The funding will be used to develop CYT X300, a multispecific antibody targeting EGFR-positive solid tumours.
Cytospire Therapeutics has completed a £61 million Series A funding round. The capital will be used to advance its 'pan-gamma delta' T-cell engager platform into first-in-man clinical trials for solid tumours. The round was led by 4BIO Capital and included investors such as Servier Ventures and the British Business Bank. Cytospire's lead candidate, CYT X300, targets EGFR-positive solid tumours, including colorectal, head and neck, and lung cancers. Preclinical data shows CYT X300 is well tolerated, avoiding cytokine storm and serious toxicities. The company is preparing for phase 1 trials after completing IND-enabling studies and GMP manufacturing.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.